Alnylam Pharmaceuticals, Inc. announced its new five-year strategy, 'Alnylam 2030,' to drive growth and patient impact.
In 2025, the company reported strong net product revenues, with a focus on TTR and Rare disease treatments.
The strategy aims to continue scaling operations, achieve global TTR leadership, innovate sustainably, and maintain profitable growth.
Revenue Growth
As a pioneer in RNAi therapeutics, Alnylam aims to continue its growth trajectory with a strategic focus on innovative treatments.
- Alnylam's 'Alnylam 2030' strategy marks a pivotal moment for the company, aiming to build on past successes and drive future growth.
- The focus on TTR diseases and sustainable innovation positions Alnylam for continued leadership in the RNAi therapeutics sector.
- The projected revenue growth for 2026 showcases the company's commitment to advancing treatments for rare diseases and driving financial performance.
Alnylam Pharmaceuticals' 'Alnylam 2030' strategy sets a clear roadmap for future growth and impact in the RNAi therapeutics landscape. With a focus on TTR diseases, sustainable innovation, and financial discipline, the company is well-positioned to achieve its ambitious goals.